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OBJECTIVES This study was designed to determine the relationship between baseline white blood cell
(WBC) count and angiographic and clinical outcomes in patients with unstable angina
(UA)/non–ST-segment elevation myocardial infarction (NSTEMI) and to see if WBC count
was a significant predictor of outcomes independent of other biomarkers.
BACKGROUND Inflammation has been shown to play a role in atherosclerosis and acute coronary syndromes.
METHODS We evaluated the relationship between baseline WBC count, other baseline variables and
biomarkers, angiographic findings, and clinical outcomes in 2,208 patients in the Treat angina
with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-
Thrombolysis In Myocardial Infarction 18 (TACTICS-TIMI 18) trial.
RESULTS Higher baseline WBC counts were associated with lower Thrombolysis In Myocardial
Infarction (TIMI) flow grades (p  0.0045) and TIMI myocardial perfusion grades (p 
0.03) as well as a greater extent of coronary artery disease (CAD) (p  0.0001). A higher
baseline WBC count was predictive of higher six-month mortality, ranging from 1.5% to
3.6% to 5.1% for patients with low, intermediate, and high WBC counts, respectively (p 
0.0017). In a multivariable proportional hazards model, patients with a low C-reactive protein
(CRP) but an elevated WBC remained at significantly higher risk of death at six months
(hazard ratio [HR] 4.3, p  0.049), and patients with a high CRP were at even higher risk
(HR 8.6, p  0.004).
CONCLUSIONS In patients with UA/NSTEMI, elevations in a simple, widely available blood test, the WBC
count, were associated with impaired epicardial and myocardial perfusion, more extensive
CAD, and higher six-month mortality. After adjustment for traditional risk factors and other
biomarkers, assessment of two inflammatory markers, WBC count and CRP, can be used to
stratify patients across an eightfold gradation of six-month mortality risk. (J Am Coll
Cardiol 2002;40:1761–8) © 2002 by the American College of Cardiology Foundation
An association between white blood cell (WBC) count and
cardiovascular disease was first noted more than a quarter of
a century ago (1). It is now appreciated that inflammation
plays a central role in atherosclerosis and acute coronary
syndromes (ACS) (2). This has led to a renewed interest in
the study of inflammatory markers, including C-reactive
protein (CRP) and, more recently, WBC count, in ACS
(3–6).
Previously, we have reported that in the setting of
ST-segment elevation myocardial infarction (MI), eleva-
tions of the baseline WBC count were associated with worse
angiographic findings as well as higher 30-day mortality (5).
We hypothesized that the same would be true of unstable
angina (UA)/non–ST-segment elevation MI (NSTEMI),
and we also hypothesized that this would be independent of
elevations of other inflammatory or myonecrosis markers.
We evaluated these hypotheses in a large cohort of patients
from the Treat Angina with Aggrastat and Determine Cost
of Therapy with an Invasive or Conservative Strategy
(TACTICS)-Thrombolysis In Myocardial Infarction
(TIMI) 18 trial (7).
METHODS
Patient population and clinical end points. The design
and main results of TACTICS-TIMI 18 were reported
previously (7). In brief, 2,220 patients with evidence of
UA/NSTEMI within the prior 24 h were randomized to an
early invasive or conservative strategy. The protocol was
approved by the relevant institutional review boards, and
written informed consent was obtained from all patients.
The prespecified clinical end points were death, nonfatal
MI, and rehospitalization for ACS; patients were followed
for six months.
WBC count and other laboratory data. Per protocol,
blood samples were obtained at baseline for WBC count,
creatinine, cardiac troponin, and CRP. The WBC count
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was determined by the laboratories at the local enrolling
institutions and was treated both as a continuous variable
and as a categorical variable, with low (6.65  109/l,
25th percentile), intermediate (6.65 to 10.11  109/l,
25th to 75th percentiles), and high (10.11 109/l,75th
percentile) levels. A serum creatinine above 1.5 mg/dl, also
determined locally, was considered elevated. Both cardiac
troponin T and CRP were assayed at the TIMI Biomarker
Core Laboratory (Boston, Massachusetts). Cardiac tropo-
nin T was measured on the Elecsys 10/10 (Roche Diagnos-
tics, Indianapolis, Indiana). We used a clinical cutpoint of
0.01 ng/ml based on prior work (8). Quantitative CRP
determination was performed with the BN II Nephelometer
(Dade-Behring, Deerfield, Illinois); the sensitivity of the
assay is 0.01 mg/dl. We used a cutoff of 1.5 mg/dl, which
corresponds to the 99th percentile value in healthy controls
(3). B-type natriuretic peptide was measured using an
established immunoassay (Biosite, San Diego, California).
Angiographic analyses. Local investigators recorded the
extent and severity of coronary artery disease (CAD) in all
patients undergoing angiography. To eliminate possible
selection bias, analyses of the association between WBC
count and extent of CAD were restricted to patients in the
invasive arm (n  983), in whom routine angiography was
mandated per protocol. Patients who underwent a percuta-
neous coronary intervention (n  538) were eligible for
enrollment in the angiographic substudy, for which angio-
graphic data were sent to the TIMI Angiographic Core
Laboratory (Boston, Massachusetts) for analysis. Throm-
bolysis In Myocardial Infarction flow grade (TFG), cor-
rected TIMI frame count, and Thrombolysis In Myocardial
Infarction myocardial perfusion grade (TMPG) were as-
sessed as previously defined (9–11).
Statistical analysis. Continuous variables were reported as
medians with interquartile ranges. Wilcoxon rank-sum and
Kruskal-Wallis tests were used for analysis of continuous
variables. The chi-squared test or the chi-square test for
linear trend was used for analysis of categorical variables.
Cumulative survival curves were calculated using the
Kaplan-Meier method. Multivariable-adjusted associations
between WBC count and angiographic findings were eval-
uated using logistic regression models, and between inflam-
matory markers and six-month mortality using Cox propor-
tional hazard models.
RESULTS
Baseline characteristics. Baseline WBC counts were avail-
able in 2,208 of the 2,220 patients in the TACTICS-TIMI
18 trial. The baseline WBC count ranged from 2.0 to 25.9
 109/l. The mean WBC count was 8.6  2.8  109/l, the
median was 8.1  109/l, and the 25th and 75th percentiles
were 6.65 and 10.11  109/l, respectively. Baseline charac-
teristics that were associated with a higher WBC count
included age 65 years, smoking, impaired renal function,
no prior aspirin use or statin use, ST-segment deviation on
the presenting electrocardiogram, an elevated cardiac tropo-
nin level, and an index diagnosis of NSTEMI (Tables 1 and
2). There was a stepwise association between degree of
smoking and WBC count: median WBC count was 7.7 
109/l in never-smokers, 7.9  109/l in former smokers, 8.1
 109/l in 10 cigarette/day smokers, 9.2  109/l in 10 to
20 cigarette/day smokers, and 9.5  109/l in 20 cigarette/
day smokers (p  0.0001).
Relationship of WBC count to angiographic findings.
There were no statistically significant differences in baseline
characteristics between patients in the angiographic sub-
study (n  538) and the overall trial cohort, including
median baseline WBC count (8.2 vs. 8.1  109/l). How-
ever, among patients in the angiographic substudy, the
baseline WBC count was higher in patients with worse
culprit artery TFG: 8.1  109/l in patients with TFG 3; 8.3
 109/l in patients with TFG 2, 8.4 109/l in patients with
TFG 1; and 9.75  109/l in patients with TFG 0 (p 
0.007). When treated as a categorical variable, higher
baseline WBC counts were associated with lower TFG,
with TFG 3 present in 71% of patients with a low WBC
count (25th percentile), 68% of patients with an interme-
diate WBC count (25th to 75th percentiles), and 54% of
patients with a high WBC count (75th percentile) (p 
0.0045, chi-squared for trend) (Fig. 1A). Similarly, the
median corrected TIMI frame count increased with increas-
ing WBC count (30 frames in patients with a low WBC
count, 32 frames in patients with an intermediate WBC
count, and 41 frames in patients with a high WBC count;
p  0.0006). A higher proportion of patients had angio-
graphically apparent thrombus with increasing WBC count
(32% vs. 35% vs. 45%; p  0.04, chi-square for trend).
Elevated baseline WBC count was also associated with
lower rates of optimal myocardial perfusion (TMPG 3)
(50% vs. 35% vs. 35%; p  0.03, chi-squared for trend). In
multivariable analyses that adjusted for potential confound-
Abbreviations and Acronyms
ACS  acute coronary syndrome
CAD  coronary artery disease
CRP  C-reactive protein
HR  hazard ratio
IL  interleukin
MI  myocardial infarction
NSTEMI  non–ST-segment elevation myocardial
infarction
OR  odds ratio
TACTICS  Treat Angina with Aggrastat and
Determine Cost of Therapy with an
Invasive or Conservative Strategy
TFG  Thrombolysis In Myocardial Infarction
flow grade
TIMI  Thrombolysis In Myocardial Infarction
TMPG  Thrombolysis In Myocardial Infarction
myocardial perfusion grade
UA  unstable angina
WBC  white blood cell
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ers including age, gender, smoking status, index diagnosis,
time to angiography, and culprit artery, a high WBC count
was associated with a longer corrected TIMI frame count
(p  0.009) and a lower likelihood of achieving TFG 3
(odds ratio [OR] 0.55, p  0.04) and TMPG 3 (OR 0.60,
p  0.09).
Beyond associations with the culprit artery, there was also
a statistically significant correlation between baseline WBC
count and the overall extent of a patient’s CAD (stenosis
50%), with higher WBC counts associated with a greater
burden of CAD (p  0.0001, chi-squared for trend) (Fig.
1B). In a multivariable logistic regression model that ad-
justed for traditional CAD risk factors, a WBC count above
the 25th percentile remained a significant predictor of
multivessel disease (OR 1.4; p  0.018). Among patients
undergoing left ventriculography, there was a statistically
significant but weak inverse association between WBC
count and left ventricular ejection fraction (Spearman’s
rho  0.08; p  0.003).
Relationship of WBC count to clinical outcomes. The
baseline WBC count was higher in patients who died within
30 days (p  0.0016) and within six months (p  0.0047)
(Table 3). There was no association between WBC count
and new or recurrent MI or rehospitalization for ACS,
either at 30 days or at 6 months. When analyzed as a
categorical variable, higher baseline WBC count was pre-
dictive of higher six-month mortality, ranging from 1.5%
among patients with a low WBC count (25th percentile)
to 3.6% among patients with an intermediate WBC count
(25th to 75th percentiles), to 5.1% among patients with a
high WBC count (75th percentile) (p  0.0017, chi-
squared for trend) (Fig. 2A). Similar trends were seen both
in patients who had UA and in those who had NSTEMI.
When stratified by baseline WBC count, event rates di-
verged over the first four weeks (p  0.0028) and then
remained roughly parallel (Fig. 2B).
There was no evidence for modification by WBC count
of the effect of an early invasive strategy. The ORs for the
composite end point for patients in the invasive versus
conservative arms were similar for patients with low (OR
0.75), intermediate (OR 0.77), and high (OR 0.82) WBC
counts, with nonsignificant heterogeneity (p  0.9). We
also examined the relationship between WBC count and
revascularization, a post-randomization decision at the dis-
cretion of the treating physician. The six-month mortality
rates across the WBC count categories were 0.6%, 3.3%,
and 7.1% among patients who were not revascularized (p 
0.0001) and 2.6%, 3.9%, and 3.1% among patients who
were (p  0.76) revascularized.
Table 1. Categorical Baseline Characteristics and WBC Count
Baseline
Characteristic
Median WBC Count Among
Patients
p Value
With
Characteristic
Without
Characteristic
Age  65 yrs 7.85 8.4  0.0001
(6.5–9.6) (6.8–10.3)
(n  954) (n  1,253)
Male 8.1 8.1 0.6
(6.7–10.0) (6.6–10.3)
(n  1,457) (n  751)
Hypertension 8.0 8.4 0.006
(6.6–9.8) (6.7–10.6)
(n  1,462) (n  746)
Diabetes 8.2 8.1 0.7
(6.6–10.0) (6.7–10.1)
(n  611) (n  1,597)
Hypercholesterolemia 8.0 8.3 0.008
(6.6–9.9) (6.7–10.4)
(n  1,342) (n  866)
Current smoker 9.1 7.8  0.0001
(7.4–11.2) (6.4–9.5)
(n  609) (n  1,479)
Elevated creatinine 8.5 8.1 0.064
(7.6–10.3) (6.6–10.1)
(n  111) (n  2,081)
Prior MI 7.9 8.3 0.0002
(6.4–9.7) (6.7–10.3)
(n  859) (n  1,349)
Prior aspirin 8.0 8.5  0.0001
(6.6–9.8) (6.8–10.7)
(n  1,470) (n  738)
Prior statin 7.8 8.25 0.0001
(6.5–9.6) (7.5–8.75)
(n  542) (n  1,666)
ST-segment deviation 8.6 7.9  0.0001
(7.0–10.6) (6.5–9.8)
(n  847) (n  1,361)
Elevated TnT 8.8 7.5  0.0001
(7.2–10.7) (6.2–9.1)
(n  995) (n  842)
Index NSTEMI 9.1 7.8  0.0001
(7.3–11.1) (6.4–9.4)
(n  823) (n  1,385)
White blood cell (WBC) count values are 109/l and are reported as medians,
interquartile ranges, and number in each group.
MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial
infarction; TnT  troponin T.
Table 2. Categorical Baseline Characteristics and WBC
Count Category
Baseline
Characteristic
WBC Count Category
p ValueLow Intermediate High
Age  65 yrs 48.6 44.4 35.3  0.0001
Male 65.4 67.2 64.0 0.6
Hypertension 66.5 69.4 59.4 0.014
Diabetes 29.4 27.6 26.2 0.24
Hypercholesterolemia 63.4 62.3 54.9 0.004
Current smoker 18.8 27.3 43.9  0.0001
Elevated creatinine 3.1 5.9 5.5 0.07
Prior MI 43.5 38.9 34.1 0.0016
Prior aspirin 69.9 68.9 58.3  0.0001
Prior statin 28.4 25.4 18.7 0.0002
ST-segment deviation 30.8 38.6 45.6  0.0001
Elevated TnT 36.8 54.7 70.9  0.0001
Index NSTEMI 24.1 36.0 53.4  0.0001
White blood cell (WBC) counts are categorized as low ( 6.65  109/l,  25th
percentile), intermediate (6.65 to 10.11  109/l, 25th to 75th percentiles), and high
( 10.11  109/l,  75th percentile).
Abbreviations as in Table 1.
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WBC count and CRP. Baseline WBC count and CRP
level were available in 1,840 patients. Although the corre-
lation between WBC count and CRP was statistically
significant (p  0.001), the strength of the correlation was
weak (Spearman’s rho  0.3). As an elevated WBC count
may be a marker of inflammation similar to CRP, we
further explored the relationship among WBC count, CRP,
and clinical outcomes. Patients were stratified by baseline
CRP level using a previously established cutoff of 1.5 mg/dl
(Table 4) (3). Among the 1,421 patients (77%) who had a
CRP level1.5 mg/dl, WBC count remained a predictor of
six-month mortality. Patients with a low WBC count
(25th percentile) had a six-month mortality of 0.8%,
whereas patients with an intermediate or high WBC count
(25th percentile) had a six-month mortality of 2% to 3%
(p 0.055). In contrast, among the 419 patients (23%) who
had an elevated CRP level (1.5 mg/dl), six-month mor-
tality was relatively high (5% to 7%) and was not statistically
different among the WBC count groups (p  0.7).
Therefore, patients were categorized into three groups
according to their combined WBC and CRP status: 1) low
WBC count (25th percentile) plus low CRP level (1.5
mg/dl); 2) high WBC count (25th percentile) plus low
CRP level; and 3) any WBC count plus high CRP level
(1.5 mg/dl). Using these two markers allowed us to risk
stratify patients across an approximate eightfold graded
increase in six-month mortality (Fig. 3). Patients with both
a low WBC count plus a low CRP level (n  397) had a
very low mortality rate (0.8%), patients with an elevated
WBC count but a low CRP level (n  1,021) had an
Figure 1. Thrombolysis In Myocardial Infarction (TIMI) flow grade (TFG) (A) and extent of coronary artery disease (B) in relation to baseline white blood
cell (WBC) count, categorized as low (25th percentile), intermediate (25th to 75th percentiles), and high (75th percentile). MultiVD  multivessel
disease; 1VD  single vessel disease; 0VD  no significant disease.
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intermediate mortality rate (2.7%), and patients with any
WBC count plus an elevated CRP level (n  420) had a
high mortality rate (6.2%) (p  0.0001 by chi-square).
Multivariable analyses. In a Cox proportional hazards
model that controlled for all potential confounders of the
effect of the inflammatory markers on outcome (including
age, gender, cardiac risk factors, prior MI, creatinine, prior
aspirin and statin use, ST-segment deviation, troponin level,
index diagnosis, and B-type natriuretic peptide level), pa-
tients with a low CRP but an elevated WBC remained at
significantly higher risk of death at six months (hazard ratio
[HR] 4.3, p  0.049), and patients with a high CRP were
at even higher risk (HR 8.6, p  0.004).
DISCUSSION
In the present study in more than 2,000 patients with
UA/NSTEMI, we observed strong relationships among
baseline WBC count, angiographic findings, and mortality,
which extend our previous observations in patients with
ST-segment elevation myocardial infarction and UA/
NSTEMI (5,6). Moreover, after adjustment for traditional
risk factors including troponin and ST-segment deviation,
simultaneous use of two inflammatory markers, WBC count
and CRP, allowed risk stratification of patients with UA/
NSTEMI across a eightfold gradation of six-month mor-
tality.
More than 25 years ago, Friedman et al. (1) observed that
an increased WBC count was associated with an increased
risk of developing an MI, and Schlant et al. (12) observed
that an elevated WBC count was a predictor of mortality
post-MI. More recently, we have demonstrated that in the
setting of STEMI, an elevated WBC count was associated
with reduced epicardial and myocardial perfusion and worse
clinical outcomes (5). We have also found that an elevated
WBC count was associated with increased short-term and
long-term mortality in the full spectrum of ACS (6). The
present study offers several important insights.
The role of inflammation in the development of CAD
and in plaque destabilization is becoming increasingly well
recognized (13). An inflammatory response is often found at
the site of plaque rupture (14), and even subtle elevations in
CRP predict a higher rate of MI in otherwise healthy
persons (15). In support of this relationship between in-
flammation and CAD is our observation that the extent of
CAD found at angiography was related to the WBC count,
even after adjusting for traditional risk factors.
There is some evidence to suggest that inflammation and
the WBC itself may directly contribute to coronary throm-
bosis, impaired perfusion, and reperfusion injury (16). In-
terleukin (IL)-6, IL-8, and CD40 ligand have been shown
to upregulate monocyte tissue factor expression, thereby
facilitating the initiation of the extrinsic pathway of the
coagulation cascade (17). Mac-1 (CD11b-CD18), which is
found on the surface of leukocytes, can directly serve as a
procoagulant by catalyzing the conversion of factor X to
factor Xa (18). Because of their large size and relatively high
cytoplasmic viscosity, leukocytes may directly cause capillary
plugging, especially in the setting of low flow and ischemia
(19). Platelet-leukocyte aggregation, mediated by Mac-1,
may also lead to thrombus formation and reduced perfusion
(20). Lastly, leukocytes may contribute to reperfusion injury
via the effects of oxygen-free radicals and complement
activation (21). Our data support these potential pathobio-
logic processes, as patients with higher WBC counts had
worse epicardial and myocardial perfusion and were more
likely to have angiographically apparent thrombus. Thus,
WBC count may be both a marker of a heightened
inflammatory state and more extensive atherosclerotic dis-
ease burden and a direct contributor to coronary artery
thrombosis and microvascular injury in the setting of plaque
rupture.
We found that an elevated baseline WBC count was
associated with a higher mortality rate, both at 30 days and
at 6 months. In contrast, there was no association between
WBC count and either MI or rehospitalization for ACS.
These observations are in agreement not only with our prior
studies of WBC count (5,6), but also with studies of other
inflammatory markers, such as CRP and IL-6, elevations of
which appear to primarily predict death rather than recur-
rent ischemic events (22–24). The basis for this remains
unknown, but the early divergence of the cumulative mor-
tality curves suggests that patients with an elevated WBC
count have a higher risk of death from the index event. This
early hazard may be related to the worse epicardial and
myocardial perfusion that we observed in these patients.
Another possibility is that WBC elevation is not a cause but
rather a consequence of acute MI and that the degree of
Table 3. Clinical Outcomes and WBC Count
End Point
WBC Count
p Value
Outcome
Present
Outcome
Absent
30 Days
Death 9.1 8.1 0.0016
(7.8–12.0) (6.6–10.0)
(n  43) (n  2,171)
MI 8.1 8.1 0.76
(6.9–9.9) (6.6–10.1)
(n  98) (n  2,116)
Rehospitalization for ACS 8.2 8.1 0.99
(6.9–9.7) (6.6–10.1)
(n  99) (n  2,115)
6 Months
Death 8.75 8.1 0.0047
(7.6–10.95) (6.6–10.0)
(n  76) (n  2,138)
MI 8.1 8.1 0.56
(6.9–10.1) (6.6–10.1)
(n  128) (n  2,086)
Rehospitalization for ACS 8.0 8.2 0.44
(6.8–9.6) (6.6–10.2)
(n  274) (n  1,940)
White blood cell (WBC) count values are  109/l and are reported as medians,
interquartile ranges, and number in each group.
ACS  acute coronary syndrome; MI  myocardial infarction.
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Figure 2. Mortality at six months (A) and cumulative mortality incidence curves (B) in relation to baseline white blood cell (WBC) count, categorized as
low (25th percentile), intermediate (25th to 75th percentiles), and high (75th percentile).
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elevation reflects the severity of the infarct. This hypothesis
was not supported by our data, in which there were only
weak correlations between WBC count and both troponin
level and left ventricular ejection fraction. Moreover, the
association between WBC count and outcome was observed
even after adjusting for troponin level and index diagnosis.
In contrast to the recent report with IL-6 in Fragmin
during Instability in Coronary Artery Disease (FRISC II)
study (24), and the observations regarding WBC count and
nonrandomized revascularization in Platelet Glycoprotein
IIB/IIIa in Unstable Angina: Receptor Suppression Using
Integrilin Therapy (PURSUIT) (25), we did not find an
interaction between inflammatory marker status and the
benefits of an invasive strategy. Our results are in keeping
with data from CRP substudies from both the FRISC II
trial (26) and the TACTICS-TIMI 18 trial (27). The
attenuated relationship between WBC count and mortality
in patients who underwent revascularization is intriguing
and may be related to the higher thrombotic burden and
hence importance of coronary interventions in patients with
an elevated WBC count. This hypothesis, and the hypoth-
esis offered by others that revascularization might itself exert
an anti-inflammatory effect, would need to be prospectively
tested in trials with randomized revascularization and serial
measurements of inflammatory markers.
An important advantage of the WBC count as a predictor
of angiographic and clinical outcomes is its ubiquity. A
WBC count is available in every hospital and, as part of the
complete blood count, is it almost universally assayed in all
patients presenting with ACS. The value for the 75th
percentile of WBC count in our study was 10.1  109/l,
which is close to the upper limit of normal for many
laboratories. Patients above this threshold had more than
three times the probability of having an occluded infarct-
related artery and more than three times the probability of
dying. As vascular-specific anti-inflammatory and antileu-
kocyte therapies are developed (15,28,29), an elevated
WBC count may help identify patients who would benefit
the most from these interventions.
We and others have shown that elevation of another
inflammatory marker, CRP, is also a powerful predictor of
recurrent events in patients with ACS (3,4,22,27). To our
knowledge, this is the first study to look at both CRP and
WBC counts in such patients. We found that patients with
an elevated CRP level had a relatively high risk of dying at
six months (5% to 7%) that was similar across WBC count
strata. In contrast, among patients with a low CRP, six-
month mortality was related to baseline WBC count:
patients had a very low mortality rate (0.8%) if they had a
low WBC count (25th percentile) and intermediate mor-
tality rates (2.2% to 2.9%) if they had higher WBC counts
(25th percentile). Thus, at centers that routinely use CRP
for risk stratification in ACS, baseline WBC count can be
used to substratify mortality risk among patients with a low
CRP level and identify patients with very low versus
intermediate six-month mortality. The relationship between
inflammatory marker status and mortality persisted even
after adjustment for potential confounders including age,
gender, cardiac risk factors, prior MI, creatinine, prior
aspirin and statin use, ST-segment deviation, troponin level,
index diagnosis, and B-type natriuretic peptide level.
There are several limitations to the present study. As an
observational investigation, it can only identify associations
and not causality. We did not collect information on WBC
differential, which may be important. Although collection of
WBC counts was a prespecified part of the analysis plan, the
relationship between WBC count and CRP must be con-
sidered exploratory.
Table 4. WBC Count, CRP, and 6-Month Mortality
CRP Level
Mortality Rate by 6 Months
p Value
WBC Percentile
<25th 25th to 75th >75th
(<6.65  109/l) (6.65 to 10.11  109/l) (>10.11  109/l)
CRP 1.5 mg/dl 0.8 2.9 2.2 0.055
(3/397) (22/748) (6/276)
CRP 1.5 mg/dl 7.1 5.1 7.1 0.7
(4/56 ) (10/195) 12/168)
White blood cell (WBC) count values are 109/l.
CRP  C-reactive protein.
Figure 3. Mortality at six months in relation to both baseline white blood
cell (WBC) count and C-reactive protein (CRP) level, categorized as low
WBC count (25th percentile) plus low CRP level (1.5 mg/dl), high
WBC count (25th percentile) plus low CRP level, and any WBC count
plus high CRP level (1.5 mg/dl).
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CONCLUSIONS
In patients with UA/NSTEMI, elevations in a simple,
widely available blood test, the WBC count, were associated
with impaired epicardial and myocardial perfusion, more
extensive CAD, and higher six-month mortality rates. Even
after adjusting for traditional risk factors including ST-
segment deviation and troponin, assessment of two inflam-
matory markers, WBC count and CRP, can be used to
stratify patients across a eightfold gradation of six-month
mortality risk.
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